Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Liposarcoma 1

Interventions

Temozolomide 7Vincristine 6Cyclophosphamide 5fludarabine 3Irinotecan 3pegfilgrastim 2irinotecan sucrosofate 2Zoledronic Acid 2Vinorelbine 2Filgrastim 2Dactinomycin 2talazoparib 1silmitasertib 1regorafenib 1pegylated granulocyte colony-stimulating factor 1pazopanib 1liposomal doxorubicin 1fludarabine phosphate 1cabozantinib 1atezolizumab 1amino-acid, glucose, and electrolyte solution 1Whole-Body Irradiation 1Vorinostat 1Tacrolimus 1Radiotherapy 1Mesna 1Melphalan 1Influenza Vaccines 1Indocyanine Green 1Immunotherapy, Adoptive 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Rhabdomyosarcoma × silmitasertib × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡